Clinical Trial

Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy

Study acronym: DAPA-MYOCANCER
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2024 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Trial Details
NCT Number NCT06711185
Lead Sponsor University of Campinas, Brazil
Conditions Breast Cancer
Enrollment 80 participants
Start Date 2024-01-30
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-02